Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Cancer Conversations: 3 Case Challenges of Real Patients With Myelodysplastic Syndromes

Join Dr. Amy DeZern, Dr. Daniel Pollyea, and Dr. Amer Zeidan as they discuss their treatment strategies for 3 patients with myelodysplastic syndromes.
Amy E. DeZern, MD, MHS
Daniel Pollyea, MD, MS
Amer Zeidan, MBBS, MPH
Released: March 14, 2022

In this podcast episode, Amy DeZern, MD, MHS, Daniel Pollyea, MD, MS, and Amer Zeidan, MBBS, discuss challenging cases in MDS, including

  • Treatment for MDS after ESA failure
  • Strategies for patients with intermediate- or high-risk MDS
  • Luspatercept therapy in MDS
  • MDS case challenges

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Bristol-Myers Squibb
Gilead Sciences, Inc.
Novartis Pharmaceuticals Corporation
Taiho Oncology Inc.

Information on this Educational Activity

Faculty

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Amy E. DeZern, MD, MHS, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Novartis, Taiho, and Takeda.
Daniel Pollyea, MD, MS

Associate Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Daniel A. Pollyea, MD, MS, has disclosed that he has received consulting fees from AbbVie, Aprea, Astellas, Bristol-Myers Squibb, Celgene, Foghorn, Genentech, Gilead Sciences, Kiadis, Novartis, Syndax, Syros, and Takeda Oncology and funds for research support from AbbVie and Teva.
Amer Zeidan, MBBS, MPH

Associate Professor, Internal Medicine
Hematology
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Amer M. Zeidan, MBBS, has disclosed that he has received funds for research support from AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Incyte, Medimmune/AstraZeneca, Novartis, Otsuka Pfizer, Takeda, and Trovagene and consulting fees from Acceleron, Agios, Amgen, Aprea, Astellas, Astex, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Epizyme, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme.

Program Medium

This program has been made available online.

Related Content

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Download these expert-selected slides on anti-BCMA CAR T-cell and bispecific agents for relapsed/refractory myeloma, from Clinical Care Options (CCO).

Noopur Raje, MD Released: September 22, 2022

Download these expert-selected slides on later-stage relapsed/refractory myeloma to help manage your patients, from Clinical Care Options (CCO).

Paul G. Richardson, MD Released: September 22, 2022

See key clinical insights fast, with this short slideset from CCO on relapsed/refractory myeloma, from Clinical Care Options (CCO).

Natalie S. Callander, MD Noopur Raje, MD Paul G. Richardson, MD Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings